A Phase 1 interventional study of JKN2501 and Placebo in Bacterial Infections, Urinary Tract Infections and Intra-Abdominal Infections, sponsored by Joincare Pharmaceutical Group Industry Co., Ltd. Recruiting at 1 site in China. Open to participants aged 18 Years to 45 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-10-03.
Sponsored by Joincare Pharmaceutical Group Industry Co., Ltd · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 32 studies in Bacterial Infections with a site in China — 10 open to participants now, 10 under way, none of them phase 3. Bacterial Infections · China.
Among the 32 studies in Bacterial Infections with a site in China, this one is the 13th largest by planned enrollment of the 16 interventional ones that give a count, is one of 3 that started in 2025, is one of 5 in phase 1, and was the 29th registered.
586 studies on the registry are indexed under Bacterial Infections; 85 are open to participants now.
Browse Bacterial Infections studies →10 of the 32 studies in Bacterial Infections with a site in China are open now. Recruiting first, the newest first:
The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School · Sites in China
Ages 18+
Eye & ENT Hospital of Fudan University · Sites in China
Ages 18+
The University of Hong Kong · Sites in China
Ages 18–100 · Healthy volunteers
Qilu Hospital of Shandong University · Sites in China
Ages 14+ · Healthy volunteers
Shandong University · Sites in China
Ages up to 18
A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →
Of the 57 Bacterial Infections studies recruiting now, 38 (67%) set no upper age limit and 14 (25%) stop at 75 or younger; 19 take children under 18; 6 take healthy volunteers.
This study: 18 Years to 45 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
32 studies; the count open now beside each. This study's row is marked.
First in 2006; this study’s year is marked. 3 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 66 is below the median of 84 across 383 interventional studies indexed under Bacterial Infections.
Median enrollment 259 across the 16 interventional studies, 628 across the 16 observational. Of the 15 that completed or were terminated, 4 (27%) have results posted.
This tab as a report to print or save as PDF → With an account.
11 of 32 have an industry lead sponsor. The 10 most frequent:
This study is registered under Joincare Pharmaceutical Group Industry Co., Ltd, one of the names counted as Joincare Pharmaceutical Group Industry Co., Ltd.. Under that name alone:
Joincare Pharmaceutical Group Industry Co., Ltd is the lead sponsor of 9 studies on the registry; 4 are open to participants now.
Joincare Pharmaceutical Group Industry Co., Ltd. has 1 study filed under Bacterial Infections — fewer than ten, so there is no comparison to draw.
1 of the studies in Bacterial Infections with a site in China that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07612163The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical SchoolClinical Efficacy and Population Pharmacokinetics of β-lactams in Cirrhotic Patients | 2026-12-31 |
Add it to your calendar (.ics) → With an account.
Among the 32 studies in Bacterial Infections with a site in China, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This Phase I study is a randomized, double-blind, placebo-controlled, dose-escalation trial conducted at a single center. It consists of two parts:
Part 1 (SAD): Evaluates the safety, tolerability, and pharmacokinetics (PK) of single ascending intravenous doses of JKN2501 in healthy adults. Biological samples (blood, urine, feces) will be collected for PK analysis.
Part 2 (MAD): Evaluates the safety, tolerability, and PK of multiple ascending intravenous doses of JKN2501 in healthy adults.
Dose levels may be adjusted based on emerging safety, tolerability, and PK data from preceding cohorts.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Excipients
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
QT and QTc
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
JKN2501 125mg only, without placebo.
Drug: JKN2501
JKN2501 B mg
Drug: JKN2501 · Drug: Placebo
JKN2501 C mg
Drug: JKN2501 · Drug: Placebo
JKN2501 D mg
Drug: JKN2501 · Drug: Placebo
JKN2501 E mg
Drug: JKN2501 · Drug: Placebo
JKN2501 F mg
Drug: JKN2501 · Drug: Placebo
JKN2501 G mg
Drug: JKN2501 · Drug: Placebo
JKN2501 H mg
Drug: JKN2501 · Drug: Placebo
Administration: Intravenous (IV) infusion.
0.9% Sodium Chloride Injection as Placebo. Administration: Intravenous (IV) infusion.
To evaluate the safety and tolerability of single and multiple intravenous (IV) infusions of JKN2501 for Injection in healthy adults.
Number of participants with treatment-related adverse events as assessed by CTCAE V5.0. An Adverse Event (AE) is defined as any untoward medical occurrence in a clinical investigation participant administered a drug; it does not necessarily have to have a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign (eg, a clinically significant abnormal laboratory finding), symptom, or disease temporally associated with the use of a drug, whether or not it is considered related to the drug. A treatment-emergent adverse event (TEAE) is defined as an adverse event with an onset that occurs after receiving study drug.
Time frame: SAD: Baseline to Day 8 post-dose. MAD: Baseline to Day 18 post-dose.
Pharmacokinetic parameter of JKN2501: Tmax
Time frame: SAD: Baseline to Day 8 post-dose. MAD: Baseline to Day 18 post-dose.
Pharmacokinetic parameter of JKN2501: Cmax
Time frame: SAD: Baseline to Day 8 post-dose. MAD: Baseline to Day 18 post-dose.
Pharmacokinetic parameter of JKN2501: t1/2
Time frame: SAD: Baseline to Day 8 post-dose. MAD: Baseline to Day 18 post-dose.
Pharmacokinetic parameter of JKN2501: AUC0-t
Time frame: SAD: Baseline to Day 8 post-dose. MAD: Baseline to Day 18 post-dose.
Pharmacokinetic parameter of JKN2501: AUC0-∞
Time frame: SAD: Baseline to Day 8 post-dose. MAD: Baseline to Day 18 post-dose.
Pharmacokinetic parameter of JKN2501: CL
Time frame: SAD: Baseline to Day 8 post-dose. MAD: Baseline to Day 18 post-dose.
Plan to share: No
No publications or documents are linked to this record.
Started Aug 2025 (actual). Primary completion is estimated for Mar 2026, 6 months after the start.
Of 52 industry-sponsored phase 1 interventional studies under Bacterial Infections, half reached primary completion within 8 months of starting (the median), counting those still running; a quarter within 3 and three quarters within 13. This study's planned 6 months is below that.
Counting every sponsor, half of 67 studies reached it within 9 months; a quarter within 4 and three quarters within 15.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Joincare Pharmaceutical Group Industry Co., Ltd →